MET and non-small cell lung carcinoma: One of the major findings of our study is that, independently from the effect on cell proliferation and growth, maintenance of gefitinib potentially limit the acquisition of a migratory and invasive phenotype in NSCLC cells characterized by MET amplification-driven resistance.